MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-12-2026
VistaGen Therapeutics Operating Expenses 2011-2026 | VTGN
Annual Operating Expenses VistaGen Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 56.5 M | 34.1 M | 59 M | 9.95 M | 10.9 M | 20.8 M | 24.6 M | 14.2 M | 11.5 M | 17.9 M | 6.78 M | 5.03 M | 6.99 M | 10.4 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 59 M | 5.03 M | 20.6 M |
Quarterly Operating Expenses VistaGen Therapeutics
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19.8 M | 20.3 M | 16 M | 15.4 M | 14.4 M | 12.2 M | 8.3 M | 7.06 M | 7.18 M | - | 9.95 M | 16.6 M | 20.1 M | 16.7 M | 10.9 M | 32.2 M | 21.3 M | 6.66 M | 5.61 M | 5.61 M | 3.63 M | 3.12 M | 5.96 M | 5.96 M | 5.35 M | 6.22 M | 7.19 M | 7.19 M | 7.43 M | 4.08 M | 2.87 M | 4.99 M | 2.26 M | 2.26 M | 3.89 M | 3.89 M | 3.1 M | 1.96 M | 2.14 M | 2.14 M | 5.39 M | 1.82 M | 1.12 M | 1.12 M | 1.11 M | 1.27 M | 1.45 M | 1.45 M | 1.22 M | 1.3 M | 1.92 M | 1.92 M | 1.68 M | 1.92 M | 2.85 M | 2.85 M | 2.12 M | 2.15 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 32.2 M | 1.11 M | 6.78 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M |  USA |
 |
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
AbbVie
ABBV
|
12.8 B | $ 210.4 | -0.34 % | $ 372 B | USA |
 |
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
50.6 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
427 M | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
5.21 K | - | -52.27 % | $ 4.45 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
98.7 M | - | -11.76 % | $ 5.79 M | USA |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
854 M | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
26 M | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
141 M | $ 12.84 | -8.02 % | $ 1.95 B | USA |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Alnylam Pharmaceuticals
ALNY
|
1.13 B | $ 320.76 | -2.25 % | $ 42 B | USA |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
142 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
120 M | - | - | $ 3.74 B | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
19.3 M | $ 1.08 | -1.06 % | $ 22.2 M | Israel |
 |
Enochian Biosciences
ENOB
|
189 M | - | - | $ 40.5 M | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Equillium
EQ
|
23.6 M | $ 1.99 | -3.4 % | $ 114 M | USA |
 |
Amgen
AMGN
|
9.33 B | $ 351.45 | -0.49 % | $ 189 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
216 M | $ 19.45 | -0.41 % | $ 909 M | USA |
 |
Amarin Corporation plc
AMRN
|
171 M | $ 14.42 | -1.7 % | $ 5.98 B |  Irlanda |
 |
Bellerophon Therapeutics
BLPH
|
22.4 M | - | -74.18 % | $ 955 K | USA |
 |
ANI Pharmaceuticals
ANIP
|
127 M | $ 73.82 | -0.43 % | $ 1.43 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
668 M | $ 46.45 | -2.31 % | $ 4.18 B |  Schweiz |
 |
Arbutus Biopharma Corporation
ABUS
|
52.2 M | $ 4.33 | -2.7 % | $ 830 M | Canada |
 |
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | USA |
 |
Brickell Biotech
BBI
|
14.4 M | - | -5.38 % | $ 6.06 M | USA |